Search results for "Lymphatic"

showing 10 items of 1179 documents

miR-155 regulative network in FLT3 mutated acute myeloid leukemia

2015

Abstract Background Acute myeloid leukemia (AML) represents a heterogeneous disorder with recurrent chromosomal alterations and molecular abnormalities. Among AML with normal karyotype (NK-AML) FLT3 activating mutation, internal tandem duplication (FLT3-ITD), is present in about 30% of patients, conferring unfavorable outcome. Our previous data demonstrated specific up-regulation of miR-155 in FLT3-ITD+ AML. miR-155 is known to be directly implicated in normal hematopoiesis and in some pathologies such as myeloid hyperplasia and acute lymphoblastic leukemia. Methods and results To investigate about the potential influence of miR-155 de-regulation in FLT3-mutated AML we generated a transcrip…

AdultMaleCancer ResearchMyeloidJUNBNetworkBiologyYoung Adultchemistry.chemical_compoundAMLhemic and lymphatic diseasesmicroRNACEBPBmedicineHumansGene silencingGene Regulatory NetworksAML; MicroRNA; NetworkAgedAged 80 and overGene Expression Regulation LeukemicGene Expression ProfilingMyeloid leukemiaMicroRNAHematologyMiddle AgedLeukemia Myeloid AcuteMicroRNAsmedicine.anatomical_structurefms-Like Tyrosine Kinase 3OncologyRUNX1chemistryMutationCancer researchFemaleMyelopoiesisK562 Cells
researchProduct

Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia

2000

The t(10;11)(p12-p13;q14-q21) observed in a subset of patients with either acute lymphoblastic leukemia or acute myeloid leukemia has been shown to result in the fusion of AF10 on chromosome 10 with CALM (also named CLTH) on chromosome 11. AF10 was originally identified as a fusion partner of MLL in the t(10;11)(p12-p13;q23) observed in myeloid leukemia. CALM is a newly isolated gene, cloned as the fusion partner of AF10 in the monocytoid cell line, U937. In order to understand the relationship between MLL, AF10, CALM and the leukemic process, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction were used to study a series of nine leukemia patients with a t…

AdultMaleCancer ResearchMyeloidOncogene Proteins FusionChromosomal translocationBiologyImmunophenotypingImmunophenotypinghemic and lymphatic diseasesAcute lymphocytic leukemiamedicineHumansCloning MolecularChildneoplasmsIn Situ Hybridization FluorescenceDNA PrimersABLBase Sequencemedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVirologyLeukemiamedicine.anatomical_structureOncologyLeukemia MyeloidAcute DiseaseCancer researchFluorescence in situ hybridizationLeukemia
researchProduct

Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases.

2008

BACKGROUND. Patients with small papillary thyroid carcinoma (PTC) may have a high incidence of regional lymph-node (LN) metastases at presentation, and these are considered to be an independent risk factor for tumor recurrence. A mutated transketolase transcript (TKTL1) has been found up-regulated in different human malignancies, and strong TKTL1 protein expression has been associated with aggressiveness and poor patient survival in several epithelial cancers. METHODS. TKTL1 protein expression was analyzed in 256 consecutive cases of PTCs ≤1.5 cm by immunohistochemistry with a specific anti-TKTL1 antibody. RNA analysis was performed by real-time polymerase chain reaction (PCR) in all cases …

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAdolescentTumor suppressor geneGene ExpressionSettore MED/08 - Anatomia PatologicaThyroid carcinomamedicineHumansThyroid NeoplasmsRisk factorLymph nodeAgedpapillary thyroid carcinoma (PTC) lymph-node (LN) metastases transketolase protein (TKTL1) tumor recurrence.biologybusiness.industryIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma Papillarymedicine.anatomical_structureOncologyLymphatic MetastasisDisease Progressionbiology.proteinCancer researchImmunohistochemistryFemaleTransketolaseAntibodybusiness
researchProduct

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

2006

We reviewed a large series of patients with essential thrombocythemia diagnosed on the basis of the Polycythemia Vera Study Group criteria, and reclassified them by evaluating their major morphologic features and clinical course using the World Health Organization classification. The morphologic review of the bone marrow biopsies of 116 patients (44 males and 72 females; aged 19 - 83 years, median 55 years; median follow-up 121 months) led to 22 cases (19%) being classified as essential thrombocythemia (ET), 24 (21%) as chronic idiopathic myelofibrosis (CIMF)-0, 44 (37%) as CIMF-1, 13 (12%) as CIMF-2, 9 (8%) as latent phase polycythemia vera, and four (3%) as chronic myeloproliferative diso…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyIdiopathic myelofibrosisSingle CenterWorld healthDiagnosis DifferentialPolycythemia veraBone Marrowhemic and lymphatic diseasesmedicineHumansPolycythemia VeraAgedAged 80 and overEssential thrombocythemiabusiness.industryHistologyBone Marrow ExaminationHematologyMiddle Agedmedicine.diseaseHaematopoiesismedicine.anatomical_structureOncologyPrimary MyelofibrosisChronic DiseaseFemaleBone marrowbusinessGranulocytesThrombocythemia EssentialLeukemialymphoma
researchProduct

Prognostic Value of Immunohistochemical Expression of Beta-1 Integrin in Pancreatic Carcinoma

1999

<i>Background: </i>Prognostically relevant factors based on the histological assessment of the resected pancreas are known. However, the knowledge of additional factors associated with the prognosis is helpful in planning the therapy for an individual patient. β<sub>1</sub> Integrin expression is known to have a prognostic influence in some malignant tumors. No data are, however, available on the prognostic value of β<sub>1</sub> integrins in pancreatic carcinoma. <i>Method: </i>We investigated paraffin-embedded specimens of 19 patients undergoing surgical treatment for periampullary carcinoma and of 42 patients for ductal pancreatic carcinoma…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPancreatic diseaseIntegrinFlow cytometryPredictive Value of TestsBeta 1 integrinHumansMedicineAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbiologybusiness.industryCell adhesion moleculeIntegrin beta1CarcinomaGeneral MedicineMiddle AgedPrognosismedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticPancreatic Neoplasmsmedicine.anatomical_structureOncologyLymphatic Metastasisbiology.proteinAdenocarcinomaImmunohistochemistryFemalebusinessPancreasOncology
researchProduct

Lymph node metastasis in lower lip squamous cell carcinoma in relation to tumour size, histologic variables and p27Kip1 protein expression.

2003

We studied a consecutive series of 95 patients undergoing radical surgical resection of lower lip squamous cell carcinoma (LLSCC) to assess the correlation between lymph node status and several prognostic variables, such as sex and age, tumour size, histologic grading, maximal microscopic tumour thickness, perineural infiltration and p27Kip1 protein status, to see which of these might be predictive of the development of lymph node metastases. Statistical analysis demonstrated a significant association between node status and tumour size, histological grading, maximal thickness, perineural invasion and p27Kip1 protein expression; additionally to node metastasis, low p27Kip1 protein expressio…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPrognostic variablePerineural invasionCell Cycle ProteinsMetastasisCarcinomamedicineHumansNeoplasm InvasivenessLymph nodeGrading (tumors)Agedbusiness.industryTumor Suppressor ProteinsHistologyMiddle AgedLymph node metastasis Sqamous cell Carcinoma Lower lip p27 tumour thcikness.medicine.diseasePrognosisImmunohistochemistrymedicine.anatomical_structureOncologyEpidermoid carcinomaLymphatic MetastasisLip NeoplasmsCarcinoma Squamous CellFemaleOral SurgerybusinessCyclin-Dependent Kinase Inhibitor p27Oral oncology
researchProduct

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997

Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T lymphocytes (CTLs) in human melanoma Regression of antigen-expressing tumors as well as selection of antigen-loss variants in the presence of antigen-specific CTLs have previously been reported. In the present study, we determined the expression of the melanocyte differentiation antigens Melan A/MART-1 and tyrosinase by mRNA analysis and by immunohistochemical staining with the monoclonal antibodies (MAbs) A103 and T311. Co-expression of Melan A/MART-1 and tyrosinase was detected by both methods in 18/20 melanomas tested. However, immunohistochemistry provided add…

AdultMaleCancer ResearchSkin Neoplasmsmedicine.drug_classBiopsyGenes MHC Class I10050 Institute of Pharmacology and Toxicology610 Medicine & healthMonoclonal antibodyPolymerase Chain ReactionMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmMHC class IHLA-A2 AntigenmedicineHumans1306 Cancer ResearchRNA MessengerMelanomaAgedDNA PrimersAged 80 and overbiologyMonophenol MonooxygenaseLiver NeoplasmsMiddle AgedImmunohistochemistryNeoplasm ProteinsCytolysisCTL*OncologyTumor progressionLymphatic MetastasisImmunologyCancer researchbiology.proteinImmunohistochemistry570 Life sciences; biologyFemale2730 Oncology
researchProduct

BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia

2009

BCL6 somatic mutations affect normal and tumoral post germinal center B-lymphocytes. Our objective was to analyse expression, mutations and polymorphisms in the BCL6 gene and to correlate those variables with the clinical outcome in early-stage chronic lymphocytic leukemia (CLL). CLL samples were used for characterisation of the mutational status of BCL6/ immunoglobulin variable heavy chain (IGHV) genes, and expression of BCL6 was determined by real time PCR and immunoblot. Out of 68 cases, 29% show somatic mutations on BCL6 which occur exclusively in IGHV mutated cases. They are single nucleotide substitutions located mainly in two short mutational hot spots. CLL cells express different le…

AdultMaleCancer ResearchSomatic cellChronic lymphocytic leukemiaBiologyPredictive Value of Testsimmune system diseaseshemic and lymphatic diseasesmedicineHumansPoint MutationGeneAgedAged 80 and overPolymorphism GeneticGenes ImmunoglobulinGerminal centerHematologyMiddle AgedPrognosismedicine.diseaseBCL6Leukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsTreatment OutcomeReal-time polymerase chain reactionOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6biology.proteinFemaleAntibodyImmunoglobulin Heavy ChainsIGHV@Leukemia & Lymphoma
researchProduct

Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.

2012

This study provides up-to-date and detailed cancer survival estimates of German patients with non-Hodgkin lymphoma (NHL, International Statistical Classification of Diseases 10th Revision [ICD-10] codes C82-C85) based on data from 11 cancer registries. Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology. Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period. Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1%. Survival decreased with age from 81.7% at age 15-49 to 46.5% at age…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentFollicular lymphomaHistory 21st CenturyYoung AdultOlder patientshemic and lymphatic diseasesInternal medicineGermanyEpidemiologymedicineHumansRegistriesAgedAged 80 and overRelative survivalbusiness.industryLymphoma Non-HodgkinCancerHematologyHistory 20th CenturyMiddle Agedmedicine.diseaseUnited StatesLymphomaOncologyImmunologyPeriod AnalysisHodgkin lymphomaFemalebusinessSEER ProgramLeukemialymphoma
researchProduct

Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.

2014

The treatment of chronic myeloid leukemia (CML) has seen several major advances over the past 30 years, notably with the introduction of interferon followed by Bcr-Abl tyrosine kinase inhibitors. We analyzed trends in the incidence of CML and patient survival in France. All cases recorded in five population-based registries between 1980 and 2009 were included. European (ESR) and world (WSR) standardized incidence rates as well as relative survival (RS) rates were estimated. We analyzed data for 781 patients (9863/3: 13.6%; 9875/3: 82.2%; 9876/3: 4.2%). ESR was 1.02 [95% confidence interval (CI) = 0.93-1.11] and WSR was 0.81 [95% CI = 0.72-0.90]. The five RS rates among patients with Philade…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulation03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansRegistrieseducationChildSurvival analysisAgedAged 80 and overeducation.field_of_studyPhiladelphia Chromosome PositiveRelative survivalbusiness.industryIncidence (epidemiology)IncidenceInfant NewbornMyeloid leukemiaCancerInfantHematologyMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolPopulation SurveillanceImmunologyDisease ProgressionFemaleFrancebusiness030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct